← Browse by Condition
Medical Condition

hcc hepatocellular carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for hcc hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hcc hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for hcc hepatocellular carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hcc hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hcc hepatocellular carcinoma?
hcc hepatocellular carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hcc hepatocellular carcinoma clinical trial?
Eligibility criteria for hcc hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Zhongda Hospital 1 trial
TaiRx, Inc. 1 trial
LaunXP Biomedical Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT07351669
Recruiting
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
Enrollment
121 pts
Location
China
Sponsor
Zhongda Hospital
View Trial →
NCT07521852 Phase 2
Recruiting
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
Enrollment
40 pts
Location
China
Sponsor
TaiRx, Inc.
View Trial →
NCT06883539 Phase 1
Recruiting
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Enrollment
24 pts
Location
Taiwan
Sponsor
LaunXP Biomedical Co., Ltd.
View Trial →

Related Conditions

tace transcatheter arterial chemoembolization (1) ct (1) solid tumor malignancies cancer (1) solid cancers (1) solid tumor cancer (1) solid tumor unspecified adult (1) solid tumour (1) solid tumors refractory to standard therapy (1) rcc renal cell cancer (1) pancreas cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology